Organogenesis (ORGO) Stock: Buy, Sell, or Hold?
ORGO - Organogenesis Holdings Inc. Class A Common Stock
$1.33
-0.07 (-5.00%)
▼
5d:
-5.67%
30d:
-20.36%
90d:
-46.37%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ORGO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ORGO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ORGO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ORGO is currently trading at $1.33, which is considered oversold relative to its 30-day fair value range of $1.39 to $1.66. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.3) compared to its historical average (18.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ORGO is in a strong downtrend. The price is currently testing key support at $1.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: ORGO scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $2.00 (+50.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ORGO is in a strong downtrend. The price is currently testing key support at $1.32. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.0% recently.
Market Sentiment: ORGO scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $2.00 (+50.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.39 -
$1.66
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.0%)
- BULLISH: Trading 50.4% below Wall St target ($2.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.39 -
$1.66
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.32
Resistance Level
$1.50
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.29
Wall Street Target
$2.00
(+50.4%)
Revenue Growth (YoY)
-56.7%
Earnings Growth (YoY)
555.2%
Profit Margin
-18.4%
PE vs Historical
-4.3 vs 18.1
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 5:27 PM ET
Data refreshes hourly during market hours. Next update: 6:27 PM
Data refreshes hourly during market hours. Next update: 6:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORGO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
